Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-02-12 (pharmabiz.net)
Biogen with decrease of -2.2% in sales -
The owner of the Super Caro Spinraza medicine published today, Wednesday, February 12, the balance corresponding to its 2024 year the US $ 9,836 million obtained in 2023. See Press release the sales of its sclerosis unit […]
Read more
2025-02-04 (marketbeat.com)
Biogen (BIIB) to Release Earnings on Tuesday |
Biogen (NASDAQ:BIIB) will be releasing earnings before the market opens on Tuesday, February 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=658031)
Read more
2025-01-06 (pressnetwork.de)
Biotech Hot Stock Announces Late Phase Gout Program. Buy this biotech stock now after 15973% with BioNTech ($BNTX)
PressNetwork – press portal for press releases and company news
Read more
2024-10-11 (csimarket.com)
Evolving SMA Therapy Promising Data on Higher-Dose Nusinersen from the DEVOTE Study Presented at WMS 2024,
*Exploring New Frontiers in Spinal Muscular Atrophy Management: Insights from the DEVOTE Study on Higher-Dose Nusinersen*Recent advancements in the treatment of spinal muscular atrophy (SMA) are shifting paradigms and offering new hope for patients and their families. At the forefront of this
Read more
2024-09-26 (life-sciences-usa.com)
Organon–Karp D: management, 202409– promoted to EVP Corporate Development before Chief Business Development Officer before Biogen + Pfizer
Life Sciences Business Intelligence Web Portal for North America, Europe and Israel
Read more
2024-08-12 (realtid.se)
Xbrane Biopharma must out-license drugs to secure financing
Biotech company Xbrane Biopharma has begun a process of out-licensing Xdivane and XB003 to secure financing until the second quarter of 2025, when it is expected to reach positive operating cash flow. It appears from a press release.
Read more
2024-08-01 (realtid.se)
Xbrane regains rights to biosimilar project
The biotechnology company Xbrane Biopharma will regain the rights to the biosimilar project BIIB801, which is a proposed copy of the drug Cimzia. It follows a decision by Biogen to terminate the commercialization and license agreement between the companies. It appears from a press release.
Read more
2024-08-01 (privataaffarer.se)
Xbrane crashes on the stock market after terminated partnership
Biogen has decided to terminate the commercialization and license agreement with Xbrane Biopharma, which means that Xbrane Biopharma will regain full rights to BIIB801. It appears from a press release.
Read more
2024-01-26 (artikel-presse.de)
Hurry: Skin cancer completely cured – Institutional investors before entry. Massive buy signal. New 224% biotech stock tip after 3,296% with BioNTech ($BNTX), 10,996% with Pfizer ($PFE), 31,205% with Amgen ($AMG) and 134,452% with Biogen ($BIIB)
The long-standing press portal Artikel-Presse.de offers current news and press releases from all over Germany.
Read more
2024-01-04 (pressnetwork.de)
Hurry: Sensational breakthrough in the fight against skin cancer - massive buy signal. 297% Biotech Hot Stock after 3,296% with BioNTech ($BNTX), 10,996% with Pfizer ($PFE), 31,205% with Amgen ($AMG) and 134,452% with Biogen ($BIIB). Now 359% with biotech shares
PressNetwork – press portal for press releases and company news
Read more
2023-12-13 (svd.se)
Leqembi launches in Japan | SvD
The Alzheimer medicine Leqembi, which was developed by the American pharmaceutical company Biogen and the Japanese Eisai and is based on a discovery by the Swedish pharmaceutical company Bioarctic, is to be launched in Japan from December 20, writes Bioarctic in a press release.
Read more
2023-11-06 (pressnetwork.de)
infactory mini thermo/hygrometer, comfort display, LCD display
PressNetwork – press portal for press releases and company news
Read more